,11–13 The levels of CNTF in the vitreous of patients and controls have not been determined for the retinal degenerations in these studies; therefore, it is not possible at this point to state whether supplying exogenous CNTF would be supplementing a deficiency or a disease-modifying therapy that is agnostic to molecular pathology. This evidence concerns the gene CNTF and retinal degeneration.